[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641182":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":21,"enrollmentInfo":65,"targetDuration":21,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":21,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tumor Microenvironment PET\u002FCT Imaging","EXPERIMENTAL","Participants with aggressive lymphoma will undergo tumor microenvironment PET\u002FCT imaging, including FAPI PET\u002FCT. Participants who are candidates for immunotherapy may also undergo Grazytracer PET\u002FCT. Imaging parameters will be analyzed to evaluate their predictive value for treatment response and prognosis.",[13,14],"Drug: Al18F-NOTA-FAPI","Drug: Al18F-NOTA-grazytracer\u002F68Ga-grazytracer",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Al18F-NOTA-FAPI","Al18F-NOTA-FAPI was injected into the patients before the PET\u002FCT scans",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Al18F-NOTA-grazytracer\u002F68Ga-grazytracer","Al18F-NOTA-grazytracer\u002F68Ga-grazytracer was injected into the patients before the PET\u002FCT scans",[9],[27],{"name":28,"affiliation":29,"role":30},"Xuejuan Wang, M.D.","Chinese Academy of Medical Sciences","STUDY_CHAIR",[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Xin Liu, M.D.","CONTACT","15621479631","liux0077@163.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"National Cancer Center\u002FCancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","Chao Yang","100021","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},{"type":55,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100641182","predictive-value-of-tumor-microenvironment-petct-for-response-and-prognosis-in-aggressive-lymphoma-a-multicenter-study-100641182",false,"NCT07657494","Predictive Value of Tumor Microenvironment PET\u002FCT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study","The Predictive Value of Tumor Microenvironment PET\u002FCT Imaging for Treatment Response and Prognosis in Aggressive Lymphoma: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Histologically confirmed aggressive lymphoma.\n* Baseline PET\u002FCT showing moderate to high FDG uptake in lymphoma lesions.\n* No previous history of malignant tumors.\n* No significant cardiac, hepatic, or renal dysfunction.\n* Expected survival of at least 6 months and ability to complete follow-up.\n\nExclusion Criteria:\n\n* Low FDG uptake on baseline PET\u002FCT.\n* Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.\n* Active or uncontrolled chronic inflammation or infection.\n* Uncontrolled diabetes mellitus.\n* Incomplete clinical data or loss to follow-up.\n* Refusal to sign the informed consent form.\n* Inability to lie supine for 30 minutes.","ALL","18 Years",{"count":66,"type":67},94,"ESTIMATED","INTERVENTIONAL",[70],"NA","This multicenter study aims to evaluate the predictive value of tumor microenvironment PET\u002FCT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET\u002FCT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET\u002FCT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.",[73],"Aggressive Lymphoma","2026-06-14",{"date":76,"type":77},"2026-06-18","ACTUAL",{"date":79,"type":77},"2024-07-11",{"date":81,"type":67},"2026-12-31",{"name":5,"class":6},1]